Market news

Supernus Pharmaceuticals (SUPN) is back in focus after reporting Q2 revenue of US$211.3 million, up 27.7% year on year, beating expectations and nudging full-year guidance higher on what management described as sustained product momentum. The upbeat quarter comes amid a more challenging period for Supernus Pharmaceuticals, with the share price down 15.1% year to date and about 13.5% lower over the past month, even though the 3-year total shareholder return of roughly 49% still points to a...

Indivior Pharmaceuticals (INDV) said Thursday that its board of directors has declared a special cas

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following September investor conferences: Cantor Global Healthcare ConferenceDate:Wednesday, September 9, 2026Fireside chat: 2:45 p.m. ETPlace: Waldorf Astoria, New York, NYWebcast Link: Here Wells Fargo Hea

Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a...

Investors need to pay close attention to SUPN stock based on the movements in the options market lately.

INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.

Supernus Pharmaceuticals has almost doubled investors' money over the past five years, yet the stock still screens as cheap on the broad valuation checks. This raises a clear question about how much of the recent merger news and growth outlook is already reflected in the price. Around 90.6% total return over five years suggests Supernus Pharmaceuticals has rewarded patient shareholders without moving into obviously stretched territory. The planned all stock merger with Indivior can support...

Detailed price information for Nexpoint Residential Trust Inc (NXRT-N) from The Globe and Mail including charting and trades.

Supernus Pharmaceuticals Inc (SUPN) raises full-year guidance on robust GOCOVRI and Qelbree sales, while advancing key CNS pipeline assets.

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.

Through this merger, the duo will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs).

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting results this Tuesday after market hours. Here’s what to look for.

It's effecting a "merger of equals" with a peer.

Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies.

Supernus Pharmaceuticals (NASDAQ:SUPN) and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing 12-month net revenue as of June 30, 2026.

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) reported second-quarter 2026 results on Monday that fell short of earnings expectations but exceeded revenue forecasts, while also announcing a merger agreement with Indivior Pharmaceuticals (NASDAQ:INDV).

Supernus (SUPN) delivered earnings and revenue surprises of 0.00% and +6.84%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 32.4% year on year to $219.1 million. The company’s full-year revenue guidance of $875 million at the midpoint came in 0.9% above analysts’ estimates. Its GAAP loss of $1.01 per share was significantly below analysts’ consensus estimates.

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.

Supernus Pharmaceuticals (SUPN) and Indivior Pharmaceuticals (INDV) said Monday that they will merge

Total revenues were $219.1 million in the second quarter 2026, a 32% increase compared to same period last year. Combined revenues of the Company's four growth products increased to $175.7 million in the second quarter 2026, representing an increase of 52% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree® , GOCOVRI®, ZURZUVAE®, and ONAPGO™. Regulatory submission to the FDA for second supplier for ONAPGO remains on-track for third quarter

Supernus Pharmaceuticals, Inc. (SUPN) reported a Q2 net loss Monday of $1.01 per share, swinging fro

Combines highly complementary businesses, with a diversified portfolio of CNS medicines totaling approximately $2.2 billion in combined annual revenuesEnhanced financial position and free cash flow generation enabling greater financial flexibility to pursue internal and external growth opportunitiesCombined company expected to benefit from immediate scale and $125 million of expected annual cost synergiesCombined entity to be named Supernus, Inc. and Jack Khattar to serve as President and Chief

Detailed price information for Supernus Pharm (SUPN-Q) from The Globe and Mail including charting and trades.

Supernus Pharmaceuticals (SUPN) is drawing attention after analysts turned more bullish on its earnings prospects, citing a positive Earnings ESP of 18.52% and a recent pattern of beating consensus estimates. See our latest analysis for Supernus Pharmaceuticals. At a share price of US$46.98, Supernus Pharmaceuticals has seen mixed short term moves, with the share price return up 1.69% over the last day but down 5.03% year to date, while the 1 year total shareholder return of 40.62% points to...

ROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call and webcast on Tuesd

Qelbree remains the first novel, non-stimulant ADHD medication approved in over a decade and is the only ADHD treatment with serotonin (5-HT2C) pharmacodynamics approved in its FDA product labeling.Qelbree has provided convenient 24-hour medication exposure for patients with ADHD ages 6 years and older, with approximately 3 million prescriptions filled since launch.As a non-controlled treatment option, Qelbree has no evidence of abuse potential and is supported by years of clinical and real-worl

Supernus (SUPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.